Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic

Similar Items

• The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  od: Syed, Maha N., i dr.
  Izdano: (2020)
• The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  od: Wan, Marilyn T., i dr.
  Izdano: (2020)
• Evaluation of the Frequency of “Not Relevant” Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis
  od: Barbieri, John S., i dr.
  Izdano: (2020)
• Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
  od: Wan, Marilyn T., i dr.
  Izdano: (2020)
• The Fundamental Pivot of Strategic Decision Making: Creativity
  od: Arastoo Towhidi
  Izdano: (2011-02-01)